1-N-叔丁氧羰基-6-甲氧基吲哚-2-硼酸 | 850568-65-9

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-N-叔丁氧羰基-6-甲氧基吲哚-2-硼酸
• 中文别名: 1-BOC-6-甲氧基吲哚-2-硼酸
• 英文名称: (1-(tert-butoxycarbonyl)-6-methoxy-1H-indol-2-yl)boronic acid
• 英文别名: [6-methoxy-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid
• CAS: 850568-65-9
• 化学式: C₁₄H₁₈BNO₅
• 分子量: 291.112
• InChiKey: ATIJYIUOXDCYTN-UHFFFAOYSA-N

物化性质

• 熔点：
  100-103
• 密度：
  1.19

计算性质

• 辛醇/水分配系数(LogP)：
  1.11
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  80.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
1-BOC-6-methoxyindole-2-boronic acid
Product Name:
Synonyms: 1-t-Butoxycarbonyl-6-methoxyindole-2-boronic acid; 1-BOC-6-methoxy-2-indoleboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
1-BOC-6-methoxyindole-2-boronic acid
Ingredient name:
CAS number: 850568-65-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C14H18BNO5
Molecular weight: 291.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-N-叔丁氧羰基-6-甲氧基吲哚-2-硼酸 在 三乙基硅烷 、 四(三苯基膦)钯 、 sodium azide 、 四丁基氟化铵 、 氨 、 sodium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三氟乙酸 、 zinc dibromide 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 185.5h， 生成 6-methoxy-2-pyrimidin-5-yl-3-[6-(1H-tetrazol-5-yl)pyridin-2-ylmethyl]-1H-indole
  参考文献：
  名称：

  INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

  摘要：

  本发明提供了一种化合物，其表示为本发明的一般式（I），具有EP1受体拮抗作用：其中A代表苯环、吡啶环或类似物；Y1代表C1-6烷基或类似物；Y2代表单键或类似物；Z代表—C(═O)—NHSO2R6、酸性5-成员杂环基团或类似物；R1代表氢原子或类似物；R2代表苯基、5-成员芳香杂环基团或类似物；R3代表卤原子、C1-6烷氧基或类似物；R4代表氢原子、卤原子或类似物；R5代表氢原子或类似物；R6代表C1-6烷基或类似物，或其药学上可接受的盐。此外，本发明的化合物（I）可用作治疗或预防LUTS的药剂，特别是OABs的各种症状。

  公开号：

  US20130317065A1
• 作为产物：
  描述：

  1-(叔丁氧基羰基)-6-甲氧基吲哚 在 硼酸三异丙酯 、 lithium diisopropyl amide 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 1-N-叔丁氧羰基-6-甲氧基吲哚-2-硼酸
  参考文献：
  名称：

  三恶唑啉/ Cu（II）催化的吲哚不对称分子内弗里德-克来夫茨烷基化反应

  摘要：

  描述了三恶唑啉/铜（II）催化的吲哚分子内Friedel-Crafts烷基化反应。这种成环法可轻松获得ee高达90％且产率高达99％的多环吲哚衍生物。

  DOI：

  10.1016/j.tet.2009.06.071

文献信息

• [EN] HETEROCYCLIC MGLU5 ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DE MGLU5
  申请人：RECORDATI IRELAND LTD

  公开号：WO2011029633A1

  公开（公告）日：2011-03-17

  Compounds (I) (R1 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotri cyclic group containing from 1 to 5 heteroatoms selected from N, O and S; R2 is H, an optionally substituted monocyclic aromatic group, or a C1-C5 heteroaromatic group containing from 1 to 4 heteroatoms selected from N, O and S; R3 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotri cyclic group containing from 1 to 5 heteroatoms selected from N, O and S; an optionally substituted mono-, bi- or tricyclic C6-C14 aryl group, an optionally substituted C3-C6 cycloalkyl group, or an optionally substituted C3-C6 cycloalkenyl group; each R4, independently for each position capable of substitution, is H or C1-C6 alkyl; R5 is H, halogen or C1-C6 alkyl; m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, or 6; and --- is an optional double bond) and their enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful for the treatment of neuromuscular dysfunction of the lower urinary tract and also for the treatment of gastrooesophageal reflux disease; anxiety disorder; abuse, substance dependence and substance withdrawal disorders; neuropathic pain disorder, migraine and fragile X syndrome disorders.

  化合物（I）（其中R1为任选取代的含1至5个选自N、O和S的杂原子的C1-C13杂单环、杂双环或杂三环基团；R2为H、任选取代的单环芳香基团或含1至4个选自N、O和S的杂原子的C1-C5杂芳香基团；R3为任选取代的含1至5个选自N、O和S的杂原子的C1-C13杂单环、杂双环或杂三环基团，任选取代的单环、双环或三环C6-C14芳基团，任选取代的C3-C6环烷基团，或任选取代的C3-C6环烯基团；每个R4独立地为每个可取代位置上的H或C1-C6烷基；R5为H、卤素或C1-C6烷基；m为0、1或2；n为0、1或2；p为0、1、2、3、4、5或6；---为任选的双键）及其对映体、非对映体、N-氧化物和药学上可接受的盐，以及含有它们的药物组合物，可用于治疗下尿路神经肌肉功能障碍以及胃食管反流病；焦虑障碍；滥用、物质依赖和物质戒断障碍；神经性疼痛障碍、偏头痛和脆性X综合征障碍。
• [EN] IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS<br/>[FR] COMPOSÉS IMIDAZO-PYRIDINE À UTILISER EN TANT QU'INHIBITEURS DE PAD
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019077631A1

  公开（公告）日：2019-04-25

  Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis. The process of preparation of the compounds of Formula (I), (II), and (III), their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, along with a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III), or a pharmaceutically acceptable salt thereof have also been described.

  公式（I）、（II）和（III）的杂环化合物以及它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物在本文中被描述。本文描述的化合物、它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物是PAD4抑制剂，可能在治疗各种疾病中有用，例如类风湿关节炎、血管炎、系统性红斑狼疮、皮肤红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、多发性硬化和牛皮癣。还描述了制备公式（I）、（II）和（III）的化合物、它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物的过程，以及包含公式（I）、公式（II）、公式（III）的化合物或其药学上可接受的盐的药物组合物。
• [EN] METHODS FOR TREATING HEPATITIS C<br/>[FR] PROCEDES POUR LE TRAITEMENT DE L'HEPATITE C
  申请人：PTC THERAPEUTICS INC

  公开号：WO2006019831A1

  公开（公告）日：2006-02-23

  In accordance with the present invention, compounds that inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.

  根据本发明，已经确定了抑制病毒复制的化合物，优选是抑制丙型肝炎病毒（HCV）复制的化合物，并提供了它们的使用方法。在本发明的一个方面，提供了用于治疗或预防病毒感染的化合物。在本发明的另一个方面，提供了用于治疗或预防HCV感染的化合物。
• Discovery and structure–activity relationship studies of indole derivatives as liver X receptor (LXR) agonists
  作者：Farid Bakir、Sunil Kher、Madhavi Pannala、Norma Wilson、Trang Nguyen、Ila Sircar、Kei Takedomi、Chiaki Fukushima、James Zapf、Kui Xu、Shao-Hui Zhang、Juping Liu、Lisa Morera、Lisa Schneider、Naoki Sakurai、Rick Jack、Jie-Fei Cheng

  DOI：10.1016/j.bmcl.2007.03.076

  日期：2007.6

  A structurally novel liver X receptor (LXR) agonist (1) was identified from internal compound collection utilizing the combination of structure-based virtual screening and high-throughput gene profiling. Compound 1 increased ABCA1 gene expression by eightfold and SREBP1c by threefold in differentiated THP-1 macrophage cell lines. Confirmation of its agonistic activity against LXR was obtained in the

  利用基于结构的虚拟筛选和高通量基因分析相结合的方法，从内部化合物收集中鉴定出一种结构新颖的肝X受体（LXR）激动剂（1）。在分化的THP-1巨噬细胞系中，化合物1使ABCA1基因表达增加了8倍，而SREBP1c增加了3倍。在辅助因子募集和报告基因反式激活测定中获得了其对LXR的激动活性的证实。描述了对化合物1的构效关系研究。
• [EN] HETEROCYCLIC PAD4 INHIBITORS<br/>[FR] INHIBITEURS DE PAD4 HÉTÉROCYCLIQUES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021163254A1

  公开（公告）日：2021-08-19

  The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.

  该披露通常涉及Formula (Ia)的取代杂环化合物，这些化合物是PAD4的抑制剂，制备这些化合物的方法，包含这些化合物的药物组合物以及使用这些化合物治疗与PAD4酶活性相关的疾病或障碍的方法。